INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| May 17, 2004 |
Director
Trans History: 742
|
Director | Form 4 | Bona fide gift | 200,000 | -- | 62,360 |
| May 17, 2004 |
Director
Trans History: 742
|
Director | Form 4 | Bona fide gift | 200,000 | -- | 200,000 |
| Nov 30, 2011 |
Director, EVP CSO President Regeneron Re
Trans History: 628
|
Director, EVP CSO President Regeneron Re | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 196,430 | $28.01 | 1,066,135 |
| Nov 30, 2011 |
Director, EVP CSO President Regeneron Re
Trans History: 628
|
Director, EVP CSO President Regeneron Re | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 196,430 | -- | -- |
| Dec 13, 2017 |
Director, President & CSO
Trans History: 628
|
Director, President & CSO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 195,438 | $21.92 | 786,786 |
| Dec 13, 2017 |
Director, President & CSO
Trans History: 628
|
Director, President & CSO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 195,438 | -- | -- |
| Dec 17, 2007 |
Director, EVP, CSO, & Pres Regn Res Labs
Trans History: 628
|
Director, EVP, CSO, & Pres Regn Res Labs | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 195,438 | -- | 195,438 |
| Dec 15, 2016 |
Director, President Regeneron Laboratori
Trans History: 628
|
Director, President Regeneron Laboratori | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 195,079 | $20.32 | 697,000 |
| Dec 15, 2016 |
Director, President Regeneron Laboratori
Trans History: 628
|
Director, President Regeneron Laboratori | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 195,079 | -- | -- |
| Dec 18, 2006 |
Director, EVP, CSO, & Pres Regn Res Labs
Trans History: 628
|
Director, EVP, CSO, & Pres Regn Res Labs | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 195,079 | -- | 195,079 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.